2025-524019-35-00RecruitingPhase 1
Three-part PK and PD study of AXN-027
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- First submitted
- 11 May 2026
- Start date
- 29 Jun 2026
- Lead sponsor
- Axonis Therapeutics Inc.
- Diseases
- Epilepsy
- EU CT number
- 2025-524019-35-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 64
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research | Leiden | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.